Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING STUDY: Lanadelumab prophylaxis in pediatric hereditary angioedema (Phase 3)
2018-002093-42Phase 3Completed
- Sponsor
- Takeda
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Safety endpoints and Pharmacokinetics of lanadelumab. Started Jul 2019; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2018-002093-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002093-42.